Spread | 0.07 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 1.51 |
Open | 1.54 |
1-Year Change | 2.67% |
Day's Range | 1.39 - 1.57 |
Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting an immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).
BRIEF: For the fiscal year ended 31 December 2021, NextCure Inc revenues decreased from $22.4M to $0K. Net loss increased 90% to $69.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income, net decrease of 70% to $1.4M (income), Research and development - Balancing val increase of 6% to $46.1M (expense).